• Explore /
  • Poster
  • / A VA Federal Supply Schedule (VAFSS)–based cost-effectiveness analysis of immunotherapy-tyrosine kinase inhibitor (IO-TKI) regimens and sunitinib in the treatment of metastatic renal cell carcinoma (mRCC).

A VA Federal Supply Schedule (VAFSS)–based cost-effectiveness analysis of immunotherapy-tyrosine kinase inhibitor (IO-TKI) regimens and sunitinib in the treatment of metastatic renal cell carcinoma (mRCC).

Abstract Poster

Authors

Manish Kohli

Manish Kohli

Huntsman Cancer Institute, Salt Lake City, UT

Manish Kohli , Zachary Cutshall , Maura Dougherty , Richard Nelson , Minkyoung Yoo

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers

Track

Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer

Sub Track

Quality of Care/Quality Improvement and Real-World Evidence

Citation

J Clin Oncol 40, 2022 (suppl 6; abstr 312)

DOI

10.1200/JCO.2022.40.6_suppl.312

Abstract #

312

Poster Bd #

E2

Abstract Disclosures

Similar Posters

First Author: Pratik Rane

First Author: Viktor Grünwald

First Author: Joseph Vento

First Author: Audreylie Lemelin